Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: irasia.com
$23.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Benitec Biopharma Ltd Announces Favourable RAC Review for Hepatitis C Therapeutic


Tuesday, 11 Jun 2013 08:08pm EDT 

Benitec Biopharma Ltd announced that the National Institutes of Health (NIH)’s Recombinant DNA Advisory Committee (RAC) gave a favourable review of the clinical protocol for the first-in-man trial for the Company’s hepatitis C therapeutic TT‐034 in a public meeting. Dr Keyur Patel of Duke University, the Principal Investigator on the trial, presented the protocol to the RAC reviewers. The meeting was held at the NIH in Washington, DC. The reviewers were generally supportive of the program and were complimentary of the protocol and of the informed consent form. Whilst formal written recommendations will be provided within the next few days, there were no requirements for any significant alteration to the protocol. As such, Benitec Biopharma, through its subsidiary Tacere Therapeutics is now moving forward to the next stages of the program – IND filing with the US FDA, and, if approved, initiation of the clinical trial. 

Company Quote

0.98
-0.055 -5.31%
29 Aug 2014